TITLE: Triptans for Migraine Headaches: Update on Clinical and Cost-Effectiveness and Guidelines for Use

DATE: 20 October 2008

RESEARCH QUESTIONS:

1. What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adults?
2. What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adolescents?
3. What is the cost-effectiveness of triptans for the treatment of migraine headache?
4. What is the evidence for the adverse events associated with triptans?
5. What are the guidelines for triptan selection for different patient populations?

METHODS:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 3, 2008), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international health technology agencies, and a focused Internet search. Results include articles published from May 2005 to Sept 2008 for Questions 1 and 4, from October 2006 to September 2008 for Questions 2 and 3, and from January 2003 to September 2008 for Question 5. Results are limited to English language publications only. Filters were applied to limit the retrieval to systematic reviews/health technology assessments and randomized controlled trials for Questions 1 and 2, economic studies for Question 3, adverse events for Question 4 and clinical practice guidelines for Question 5. Internet links are provided, where available.

RESULTS:

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by economic evaluations, randomized controlled trials, observational studies, and evidence-based guidelines.

Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information on available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
This report is an update to a previous HTIS report (I4001: Triptans for acute migraine: comparative clinical effectiveness and cost-effectiveness). It provides literature that has been published since the release of the previous report and further information regarding adverse events and guidelines. No head-to-head trials were found regarding the comparative clinical effectiveness of triptans in adolescents. One randomized controlled trial was identified, comparing almotriptan to placebo.

Research question 1: What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adults?

Systematic reviews and meta-analyses


Randomized controlled trials


Research question 2: What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adolescents?

Randomized controlled trials


Research question 3: What is the cost-effectiveness of triptans for the treatment of migraine headache?

Economic analyses and cost information


Research question 4: What is the evidence for the adverse events associated with triptans?

Observational studies


Guidelines and recommendations


Research question 5: What are the guidelines for triptan selection for different patient populations?

Guidelines and recommendations

*Adults or Adults and Adolescents*


Adolescents


PREPARED BY:
Lynda McGahan, MSc, Research Officer
Carolyn Spry, MLIS, Information Specialist
Health Technology Inquiry Service
Email: [htis@cadth.ca](mailto:htis@cadth.ca)
Tel: 1-866-898-8439
APPENDIX – FURTHER INFORMATION:

Research question 1: What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adults?

Systematic reviews and meta-analyses


Review articles


Observational studies


Research question 2: What is the comparative clinical effectiveness of triptans for the treatment of migraine headache in adolescents?

Randomized controlled trials


Research question 5: What are the guidelines for triptan selection for different patient populations?

Systematic review